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Polo-like kinase 1 (PLK1) is one of the serine threonine kinases that contributes to cell mitosis and is regarded as a marker of cellular
proliferation. However, its protein expression in human carcinoma has not been studied in depth. We investigated PLK1 expression
in various thyroid neoplasms in order to elucidate its physiological significance in thyroid carcinoma. Normal follicular cells only
occasionally expressed PLK1. In follicular tumours and anaplastic carcinoma, PLK1 overexpression was not a common event and only
5.9% of follicular adenoma, 7.1% of follicular carcinoma, and 11.8% of anaplastic carcinoma overexpressed this protein. However,
43.7% of papillary carcinoma overexpressed PLK1. Polo-like kinase 1 overexpression was more frequently observed in smaller
papillary carcinoma lesions, and 62.5% of microcarcinoma (ranging from 4mm to 1.0cm) and even 66.7% of incidental carcinoma
(less than 4mm) overexpressed it, whereas this phenomenon could only be seen in 20.0% of lesions larger than 4.0cm. Furthermore,
PLK1 overexpression was not related to cell-proliferating activity evaluated by Ki-67 labelling index, but it was inversely linked to
UICC stage, extrathyroidal invasion, and the presence of poorly differentiated lesion as proposed by Sakamoto et al. These findings
strongly suggest that, unlike other carcinomas previously studied, PLK1 does not act as a cell cycle regulator but plays a constitutive
role in papillary carcinoma especially in the early phase, and may contribute to the malignant transformation of this carcinoma.
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Thyroid carcinoma is one of the most common malignancies
originating in the endocrine glands. There are two prominent
histological types of thyroid carcinoma originating from follicular
cells, papillary carcinoma and follicular carcinoma, which is
comparatively rare. Follicular carcinoma is thought to arise from
pre-existing follicular adenoma, although this has not yet been
confirmed. The precursor lesion of papillary carcinoma has not yet
been identified (Fagin, 2000). Generally, the biological activity of
papillary carcinomas is mild, but when these lesions dedifferenti-
ate and turn to anaplastic carcinoma (undifferentiated carcinoma),
they grow rapidly and patients usually have a dire prognosis
despite various therapeutic strategies (Aldinger et al, 1978). These
polarised characteristics are typical of thyroid carcinoma, prompt-
ing many researchers to investigate factors linked to or triggering
dedifferentiation. From a morphological perspective, Sakamoto
et al (1983)found that papillary or follicular carcinoma with typical
growth patterns, such as a solid, trabecular, or scirrhous pattern,
shows a poorer prognosis than that with a pure papillary or
follicular pattern only. Therefore, they hypothesised that these
carcinomas are dedifferentiating, and designated such lesions as
poorly differentiated carcinoma, although this hypothesis has not
been confirmed.
For the development of neoplasm, the activity of cell cycle
progression, including mitosis, is important. To date, expression
of various regulators of this event has been investigated in
human neoplasms, including thyroid carcinoma. Polo-like kinase 1
(PLK1) is a serine threonine kinase, which belongs to the polo-like
kinases (PLKs) family homologous to the Drosophila polo
kinase (Golsteyn et al, 1994; Hamanaka et al, 1994). This protein
is closely associated with cell cycle regulation. Golsteyn et al
(1995) showed that, although the level of PLK1 protein expression
is low in the G1 phase, it elevates in the S phase following maximal
level in the G2/M phase. They also proved that its activity is
also elevated during cell mitosis. Using cell lines and human
carcinoma tissues, another group also demonstrated that PLK1 is a
marker of cell proliferation, which could be useful for carcinoma
diagnosis and may be a target for cancer chemotherapy (Holtrich
et al, 1994; Yuan et al, 1997). To date, however, PLK mRNA
expression has been investigated for a large number of human
carcinoma specimens of only a few origins (Wolf et al, 1997;
Knecht et al, 1999; Tokumitsu et al, 1999). In addition, PLK1
protein expression has been studied only for colorectum
carcinoma (Takahashi et al, 2003), indicating that our knowledge
of PLK1 expression and its physiological role in human carcinoma
remains limited.
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thyroid neoplasms, to elucidate whether this kinase is associated
with progression of this carcinoma.
MATERIALS AND METHODS
Cell line
A thyroid tumour cell line, NPA (papillary carcinoma), was
established by our co-workers. Cells were cultured in Dulbecco’s
modified Eagle’s medium (Nihonseiyaku, Tokyo, Japan) supple-
mented with 10% fetal calf serum (Dainippon Pharmaceutical,
Tokyo, Japan), 500Uml
 1 penicillin (Gibco BRL, MD, USA), and
500mgml
 1 streptomycin.
Tissue specimens
Tissue specimens of thyroid neoplasms were obtained from 149
patients who underwent surgery in the Department of Surgery,
Kuma Hospital. This project was approved by the ethics committee
of the hospital and informed consent was obtained from the
participating patients. Our series involved 17 anaplastic (undiffer-
entiated) carcinomas. These patients underwent surgery between
1987 and 2002. Between 1999 and 2001, 1205 patients underwent
surgery for papillary or follicular carcinoma, and 155 (12.9%) had
lesions with solid, trabecular, or scirrhous growth patterns
diagnosed as poorly differentiated carcinoma, as proposed by
Sakamoto et al (1983). From these patients, we selected 87
papillary carcinomas and 28 follicular carcinomas (eight widely
invasive and 20 minimally invasive carcinomas) for the present
study. Of these cases, 28 papillary carcinomas and three follicular
carcinomas were diagnosed as including poorly differentiated
lesions according to Sakamoto et al (1983). Among this series of
papillary carcinomas, 36 cases were diagnosed as microcarcinoma
according to the WHO classification, because the maximal
diameters were 1.0cm or less (Hedinger et al, 1988). Generally,
ultrasonography can detect tumours measuring 4mm or more. In
all, 24 of 36 cases were preoperatively diagnosed and surgical
treatment was performed for the disease. However, the remaining
12 cases had not been detected by ultrasonography and were
incidentally found in specimens following surgery for other
thyroid diseases such as follicular adenoma, adenomatous goiter,
and diffuse hyperplasia. In these cases, the maximal diameters
were 3mm or less. In addition, we selected 17 follicular adenomas
from patients (Hedinger et al, 1988) who underwent surgery in
2002. For immunohistochemical study, tissues were fixed in 10%
formalin and paraffin-embedded. For Western blot analysis,
tissues were snap frozen in liquid nitrogen and stored at  801C
until used.
Antibody
A mouse monoclonal anti-human PLK1 antibody and anti-Ki-67
antibody were obtained from Transduction Laboratories (Lex-
ington, KY, USA) and Ylem (Rome, Italy), respectively. These were
applied at concentrations of 1:100 and 1:50, respectively.
Western blot analysis
For Western blotting of PLK1, 20mg of proteins extracted from
tissue specimens was electrophoresed on an 8% polyacrylamide
gel. After blotting onto a PVDF membrane, the membrane filter
was incubated with 1/1000 diluted anti-human PLK antibody at a
concentration of 1:200 for 2h at room temperature. The filter was
washed three times with TBS containing 0.05% Tween 20 for
10min each and then incubated with TBS containing 1/2500
diluted peroxidase-conjugated goat antibody to mouse IgG
(Promega, USA) for 1h. After washing the membrane three times
with TBS containing 0.05% Tween 20 for 10min each, it was
developed by an enhanced chemiluminescence system (ECL,
Amersham) according to the manufacturer’s protocol.
Immunohistochemistry
Tissue sections 4mm thick were dewaxed and endogenous
peroxidase activity was blocked with 0.3% hydrogen peroxide in
methanol for 15min. For antigen retrieval, sections were immersed
in 0.03moll
 1 citrate buffer and incubated at 951C for 40min.
After rinsing in phosphate-buffered saline pH 7.2 (PBS), 10%
bovine serum (Wako, Osaka, Japan) was applied for 20min to
block nonspecific reactions. Then, sections were incubated with a
primary antibody at 41C overnight. After rinsing in PBS, specimens
were treated with peroxidase-labelled anti-mouse and anti-rabbit
immunoglobulins (Nichirei, Tokyo, Japan) for 30min. The
peroxidase reaction was visualised by incubating the sections with
0.02% 3,30-diaminobenzidine tetrahydrochloride in 0.05 M Tris
buffer with 0.01% hydrogen peroxide (Nichirei, Tokyo, Japan). The
sections were counterstained with haematoxylin. Sections for the
negative control were prepared using mouse immunoglobulin
instead of primary antibody.
Immunohistochemical evaluation
Polo-like kinase 1 immunoreactivity was observed predominantly
in the cytoplasm, and we regarded cells positive for PLK1 only
when the immunoreactivity was clearly observed. Based on the
positive tumour cell rate, we categorised all cases into four groups:
( ), 0–5%; (þ), 6–29%; (þþ), 30–59%; and (þþþ), more
than 60%. Cases graded as (þþ)o r(þþþ) were regarded as
highly overexpressing PLK1, whereas those graded as ( )o r(þ)
were judged as showing low expression of PLK1. This categorisa-
tion is fundamentally similar to that in a previous immunohisto-
chemical study using the same antibody (Takahashi et al, 2003).
We counted cells positive for Ki-67 by evaluating at least 300
cells in at least three randomly selected fields and calculated the
labelling index (LI) for Ki-67. In papillary carcinoma, cases
showing Ki-67 LI larger than 3% were classified as the high group.
Statistical analyses
Fisher’s exact probability test was adopted to examine the
relationship between variables. A P-value less than 0.05 was
considered significant.
RESULTS
Western blot analysis for PLK1 in thyroid tissues and cell
lines
We investigated the expression of PLK1 in thyroid carcinomas and
cell lines using Western blot analysis (Figure 1). Lanes 1–5
indicated papillary carcinoma, and lanes 2, 3, and 5 were positive
for PLK1. Lanes 6–10 were follicular carcinomas, and lane 6 was
the only positive case of PLK. There were no signals observed in
normal thyroid tissues (lanes 11–14, Figure 1). Lanes 15–17
indicated anaplastic carcinomas, and a signal for PLK1 as a single
band at 67kDa was observed in one case in lane 17. Polo-like
kinase 1 signal was found in a thyroid carcinoma cell line, NPA
(lane 18). These results for tissue specimens were coincident with
our immunohistochemical findings in each case.
Immunohistochemistry for PLK1 in thyroid neoplasms
Polo-like kinase 1 was only occasionally expressed in normal
follicular cells, as well as infiltrating lymphocytes (Figure 2A).
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is summarised in Table 1.
Follicular carcinoma and adenoma
In follicular tumours, PLK1 overexpression was not frequently
observed. Only one of the 17 adenomas (5.9%) and two of the 28
carcinomas (7.1%) were classified in the high group (Figure 2B).
There was no significant difference in the incidence of PLK1
overexpression between follicular adenoma and carcinoma.
Papillary carcinoma
Papillary carcinoma overexpressed PLK1 more frequently than
follicular carcinoma (P¼0.0002), and 38 cases were judged in the
high group (43.7%) (Figure 2C). Among the papillary carcinomas
in this study, 36 cases were microcarcinoma with maximal
diameters of 1.0cm or less. Of these lesions, 24 were preoperatively
diagnosed and their sizes ranged from 4mm to 1.0cm. Polo-like
kinase 1 overexpression was observed in 15 of these cases (62.5%).
Furthermore, the remaining 12 cases were incidental carcinomas,
3mm in diameter or smaller. Also in these cases, PLK1 was
frequently overexpressed and eight cases (66.7%) were regarded in
the high group. As shown in Table 2, larger papillary carcinomas
showed a decrease in PLK1 expression (P¼0.0020), and of 15
tumours larger than 4.0cm, only three (20.0%) overexpressed
PLK1.
We investigated the relationship between PLK1 overexpression
and other clinicopathological parameters of papillary carcinoma
(Table 3). For this analysis, incidental carcinomas were omitted,
because most parameters for these cases were unknown. Polo-like
kinase overexpression was inversely linked to UICC early stage
(P¼0.0093), extrathyroidal invasion (P¼0.0372), and the pre-
sence of a lesion showing solid, trabecular, or scirrhous growth
pattern (P¼0.0005). Furthermore, we compared PLK1 expression
and Ki-67 LI in papillary carcinoma. Generally, cell-proliferating
activity of thyroid carcinoma except for anaplastic carcinoma is
very low. Also in papillary carcinoma in our series, when we set the
cutoff value at 3%, only 17 cases were classified in the high group.
As shown in Figure 2C and D, coexpression of PLK1 and Ki-67 was
only occasionally seen, and we could not establish any relationship
between PLK1 expression and Ki-67 LI in papillary carcinoma
(Table 3).
Anaplastic carcinoma
Anaplastic carcinoma originats from papillary and follicular
carcinomas, and has a high activity of development. Indeed, in
our series, Ki-67 LI was high and averaged 38.7þ16.6 (15.3–60.9).
However, in this carcinoma, PLK1 overexpression was seen only in
two of the 17 cases (11.8%) (Figure 2E), and the incidence was
significantly lower than that in papillary carcinoma (P¼0.0143).
Furthermore, we could not find any relationship between PLK1
expression and Ki-67 antigen expression in this carcinoma (Figure
2E and F).
Figure 1 Western blot of PLK1 on thyroid carcinoma tissues and thyroid
tumour cell lines. Twentymg of total cellular proteins were electrophoresed
on 12% SDS-PAGE and then Western blot of PLK1 was performed as
described in Materials and Methods. Lanes 1–5 indicate papillary
carcinoma, lanes 6–10 follicular carcinoma, lanes 11–14 normal thyroid
tissue, lanes 15–17 anaplastic carcinoma, and lane 18 thyroid carcinoma
cell line, NPA.
Figure 2 Immunostaining of PLK1 and Ki-67 in thyroid tissues. (A) PLK1
was not expressed in normal follicules. (B) Absence of PLK1 expression in
follicular carcinoma. (C) PLK1 overexpression in papillary carcinoma. (D)
Absence of Ki-67 antigen expression in a serial section with (C). (E) PLK1
was not overexpressed in anaplastic carcinoma. (F) Ki-67 antigen
expression is frequently observed in a serial section with (E) Scale bar
150mm.
Table 1 Expression of PLK1 in thyroid neoplasms
PLK1 expression
Low High
Histological type   + ++ ++ Total
Anaplastic caccinoma* 7 8 0 2 17
Papillary carcinoma*
,** 26 23 27 11 87
Follicular carcinoma** 21 5 2 0 28
Follicular adenoma 14 2 1 0 17
*P¼0.0143, **P¼0.0002.
Table 2 Relationship between PLK1 expression in papillary carcinoma
and tumour size
PLK1 expression
Low High
  + ++ ++ Total
p0.3cm
a,b 2262 1 2
40.3cm, p1.0cm
b 8 1 11 4 24
41.0cm, o4.0cm
c 91 51 0 2 3 6
44.0cm
c 7503 1 5
Total 26 23 27 11 87
aThese carcinomas were incidentally found in surgical specimens resected for other
thyroid diseases (incidental carcinoma). b vs c: P¼0.0020.
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In this study, we demonstrated that (1) follicular cells in normal
follicles only occasionally expressed PLK1, (2) the incidence of
PLK1 overexpression was not high in either follicular tumours or
anaplastic carcinoma, and (3) in papillary carcinoma, PLK1
overexpression was more frequently observed in cases showing
low biologically aggressive phenotypes, although it was not related
to cell-proliferating activity.
To date, PLK mRNA expression has been studied in a few types
of carcinoma such as non-small cell lung carcinoma, squamous cell
carcinoma of the head and neck, gastric carcinoma, and
oesophageal carcinoma (Wolf et al, 1997; Knecht et al, 1999;
Tokumitsu et al, 1999). Except for that in gastric carcinoma, the
PLK mRNA level in these carcinomas was directly linked to the
biologically aggressive phenotype of the tumour and/or worse
prognosis for the patient (Wolf et al, 1997; Knecht et al, 1999;
Tokumitsu et al, 1999). Furthermore, Takahashi et al (2003)
demonstrated that, in human colorectal carcinoma, PLK1 protein
overexpression was directly related to the proliferating cell nuclear
antigen (PCNA) LI, as well as some other parameters reflecting the
biological aggressiveness of the tumour such as Dukes’ classifica-
tion, primary tumour invasion, lymph node metastasis, and
aberrant p53 expression. These results are not discrepant
with and even supported by those obtained from previous
in vitro studies that PLK1 plays a significant role in cell-
proliferating activity (Holtrich et al, 1994; Golsteyn et al, 1995;
Yuan et al, 1997).
However, our findings are sharply in contrast with those in
other carcinomas, and the physiological significance of PLK1 in
thyroid tumours seems complicated. A high incidence of PLK1
overexpression was observed in papillary carcinoma. As previously
reported, cell-proliferating activity of papillary carcinoma is
generally low (Erickson et al, 1998), and in our series, Ki-67 LI
was less than 3% in most cases. We investigated the relationship
between PLK1 overexpression and cell-proliferating activity of
papillary carcinoma, but there was no association detected,
indicating that PLK1 does not play a role in regulating cell
proliferation. Instead, we found that PLK1 is more frequently
overexpressed in papillary carcinoma with low biological aggres-
siveness, because its expression was inversely linked to certain
clinicopathological parameters such as tumour size, UICC stage,
extrathyroidal invasion, and the presence of poorly differentiated
lesion. Especially, it is interesting to that PLK1 is more frequently
overexpressed in papillary microcarcinoma and even in incidental
carcinoma, which is smaller than 4mm in maximal diameter.
Recently, we performed a trial of observation without surgical
treatment for papillary microcarcinoma patients, and found
that most of these tumours do not enlarge, indicating that these
lesions do not grow or grow only slowly (Ito et al, 2003). These
findings strongly suggest that PLK1 is not related to growth of
papillary carcinoma. Another interesting finding is the frequent
lack of PLK1 expression in anaplastic carcinoma. Anaplastic
carcinoma is known to arise from papillary and follicular
carcinomas and has high mitotic activity as demonstrated by
Erickson et al (1998) as well as this study. However, in our series,
PLK1 overexpression was observed only in 11.8% of cases.
According to these findings, we can conclude that PLK1 is not
likely to contribute directly to the mitosis of papillary carcinoma
cells. This means that the physiological significance of PLK1 in
thyroid papillary carcinoma is unique and completely different
from that in all other carcinomas studied to date. One explanation
of these results is that PLK1 plays an oncogenic role and is
constitutively required in papillary carcinoma during the early
phase, while it is less necessary for the development of this
carcinoma during the advanced stage. Although the mechanism of
malignant transformation from normal follicle to papillary
carcinoma remains to be elucidated, our finding that PLK1 is
frequently overexpressed in incidental carcinomas suggests that
PLK1 expression may even play a role in the carcinogenesis of
papillary carcinoma.
In follicular tumours, PLK1 overexpression was not frequently
detected, and there was no significant difference in the incidence
between follicular carcinoma and follicular adenoma. It is there-
fore suggested that this protein is not likely to play a role in the
progression of this tumour or in the transformation of follicular
adenoma to carcinoma.
In summary, the findings of this study strongly suggest that
PLK1 plays a constitutive role in thyroid papillary carcinoma
especially during the early phase, and may be related to the
malignant transformation of this lesion. Further studies are
necessary to elucidate the detailed mechanism by which this
protein contributes to carcinogenesis and the development of this
carcinoma.
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